Adipothera
Adipothera develops therapies targeting the stromal microenvironment to treat diseases driven by fibrosis and inflammation. Using AI, computation, and multi-modal datasets, the company generates and validates drug candidates aimed at repairing tissue rather than managing symptoms. Their approach focuses on stromal reprogramming for conditions such as radiation injury, lymphedema, and pathological bone formation.
What We Do
A topical drug candidate designed for local delivery to stromal targets in conditions such as radiation injury and lymphedema.
An oral drug candidate for systemic modulation of stromal activation, focused on mitigating flare events in FOP/HO.
A topical drug candidate designed for local delivery to stromal targets in conditions such as radiation injury and lymphedema.
An oral drug candidate for systemic modulation of stromal activation, focused on mitigating flare events in FOP/HO.
Application Area
Regenerative Medicine
Digital Health Technologies
Services
Key People
Chief Executive Officer and Founder
Founder and Board Member
Scientific Advisory Board Member
Chief Executive Officer and Founder
Founder and Board Member
Scientific Advisory Board Member
News & Updates
Core technology for programming stromal responses is validated, enabling new classes of drug targets.
Progress in advanced preclinical studies guides further development and dose selection for the oral candidate.
Submission of preclinical results for the AT-002 program to a high-impact translational journal.
Intellectual property filings covering proprietary chemical series that underpin the company's lead candidates.
Core technology for programming stromal responses is validated, enabling new classes of drug targets.
Progress in advanced preclinical studies guides further development and dose selection for the oral candidate.
Submission of preclinical results for the AT-002 program to a high-impact translational journal.
Intellectual property filings covering proprietary chemical series that underpin the company's lead candidates.